IL-5 signaling in asthmatic derived fibroblasts exacerbates airway remodeling through ECM dysregulation and apoptosis resistance
- PMID: 41188935
- PMCID: PMC12584347
- DOI: 10.1186/s12931-025-03371-x
IL-5 signaling in asthmatic derived fibroblasts exacerbates airway remodeling through ECM dysregulation and apoptosis resistance
Abstract
Background: Airway remodelling, a critical feature of severe asthma, involves fibroblast-driven extracellular matrix (ECM) dysregulation. While IL-5 is pivotal in eosinophilic inflammation, its direct role in fibroblast-mediated fibrosis remains undefined.
Methods: Primary lung fibroblasts from asthmatic and healthy donors were stimulated with 0.5 ng/ml of IL-5 for several time points. ECM components, Matrix metalloproteinases (MMPs), Tissue inhibitor of metalloproteinases (TIMPs), and cytokines were analysed via quantitative real time-PCR (qRT-PCR), Western blot, ELISA, and flow cytometry. RNA sequencing and absolute gene set enrichment analysis (absGSEA) identified signaling pathways. Apoptosis was assessed using Annexin V/PI staining.
Results: IL-5 shown to markedly increase the expression of ECM proteins, including collagen I and fibronectin, in asthmatic fibroblasts. It also upregulated MMP-2 and MMP-3 expression, alongside increased levels of TIMP-1 and TIMP-2. Moreover, IL-5 promoted the secretion of IL-6 and TGF-β. RNA-seq analysis identified 472 differentially expressed genes in asthmatic fibroblasts, highlighting activation of the MAPK pathway and suppression of apoptosis through NR4A1 upregulation. IL-5 further reduced fibroblast apoptosis and enhanced IL-5Rα expression, indicating potential autocrine signalling.
Conclusion: IL-5 directly activates lung fibroblasts to drive airway remodelling in severe asthma through ECM deposition, MMP/TIMP imbalance, and pro-fibrotic cytokine secretion, positioning it as a dual mediator of inflammation and fibrosis with novel therapeutic potential.
Keywords: Airway Remodeling; Asthma; Fibrosis; Interlukin-5 (IL-5).
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The healthy and asthmatic human primary fibroblast cells used in this study were obtained from Lonza. As the cells were obtained from a commercial source and not directly from human participants, this study did not require ethics committee approval. All the patient’s information provided is sourced from Lonza based on our request. Consent for publication: Not applicable. Competing interests: Bassam Mahboub has received research funding from GlaxoSmithKline to support research conducted as part of this study.
Figures
References
-
- Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(S1). 10.1002/alr.21609. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
